Adverse events that occurred in at least 10 % of patients in either teriflunomide group and with an incidence that was at least 2 % higher than that with placebo were increased alanine aminotransferase ( 40 [ 19 % ] of 216 patients in the 14 mg group , 36 [ 17 % ] of 207 in the 7 mg group vs 27 [ 14 % ] of 191 in the placebo group ) , hair thinning ( 25 [ 12 % ] and 12 [ 6 % ] vs 15 [ 8 % ] ) , diarrhoea ( 23 [ 11 % ] and 28 [ 14 % ] vs 12 [ 6 % ] ) , paraesthesia ( 22 [ 10 % ] and 11 [ 5 % ] vs 10 [ 5 % ] ) , and upper respiratory tract infection ( 20 [ 9 % ] and 23 [ 11 % ] vs 14 [ 7 % ] ) .